17328-67-5

Basic information

• Product Name: Cyclohexanone, 4-(1-hydroxy-1-methylethyl)-
• CAS NO: 17328-67-5
• Molecular Formula: C9H16O2
• Molecular Weight: 156.225
• Mol File: 17328-67-5.mol

Chemical Properties

• CAS DataBase Reference: Cyclohexanone, 4-(1-hydroxy-1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanone, 4-(1-hydroxy-1-methylethyl)-(17328-67-5)
• EPA Substance Registry System: Cyclohexanone, 4-(1-hydroxy-1-methylethyl)-(17328-67-5)

Safety Data

• Hazardous Substances Data: 17328-67-5(Hazardous Substances Data)

Upstream product

• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 917-54-4 methyllithium 
• 5432-85-9 4-isopropyl-cyclohexanone 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 75-16-1 methylmagnesium bromide 
• 917-64-6 methyl magnesium iodide 
• 38651-65-9 (1R,5S)-(+)-nopinone 

Relevant articles and documents

Fluorination or hydroxylation of non activated C-H bonds in amides and ketones using CCl4 or NBS in superacids

Amides and ketones are fluorinated or hydroxylated in HF-SbF5 in the presence of CCl4 or NBS, reaction occurring at a carbon far located from the functional group.

Control of transient aluminum-aminals for masking and unmasking reactive carbonyl groups

A new reagent, the dimethylaluminum N,O-dimethylhydroxylamine complex, is effective at masking reactive carbonyl groups in situ from nucleophilic addition. This reagent allows chemoselective addition of reducing reagents, Grignard reagents, organolithiums, Wittig reagents, and enolates into substrates with multiple carbonyl groups. Moreover, the trapped carbonyl group, a stable aminal, can be unmasked in situ for additional synthetic manipulations.

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY

The present invention provides compounds of Formula (I) (wherein R1, R3, X, W, Z and ring Y are as defined herein). The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity.

Functionalization of non-activated C-H bonds in ketones and imines with HF/SbF5/CCl4

Reaction of cyclic ketones 2-6 and imines 15-17 in HF/SbF5 in presence of CCl4 yield hydroxy or fluoroderivatives, hydride abstraction occurring at a site located far from the functional group. Whereas ketones 2-5 yield only hydroxy derivatives, through cyclic carboxonium ion, imines 15, 16 N-protonated in the media conditions give only fluoroderivatives 18, 19, respectively, after quenching with HF-pyridine. Ring contraction is operative when starting from large membered ring ketones 24 and 25, and imine 26, leading to a mixture of hydroxy or fluoro cyclohexanones and/or cycloheptanones.